Tissue Distribution of the Novel DPP-4 Inhibitor BI 1356 is Dominated by Saturable Binding to its Target in Rats

被引:86
作者
Fuchs, Holger [1 ]
Binder, Rudolf [1 ]
Greischel, Andreas [1 ]
机构
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Drug Metab & Pharmacokinet, D-88397 Biberach, Germany
关键词
BI; 1356; pharmacokinetics; linagliptin; dipeptidyl peptidase 4; tissue distribution; DIPEPTIDYL-PEPTIDASE-IV; PHARMACOKINETICS; DEGRADATION; BI-1356;
D O I
10.1002/bdd.662
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BI 1356 (INN: linagliptin) is an inhibitor of dipeptidyl peptidase-4 (I)PP-4). This study investigated whether saturable binding of BI 1356 to its target DPP-4 occurs in tissues and whether drug accumulation occurs at these sites in vivo. In order to test these hypotheses, the tissue distribution of BI 1356 was determined in wild-type and DPP-4 deficient rats at different dose levels by means of whole body autoradiography and measurement of tissue radioactivity concentrations after single i.v. dosing of [(14)C]-radio labeled BI 1356. The accumulation behavior of drug-related radioactivity in tissues was further explored in an oral repeat dose study. Tissue levels of [(14)C]BI 1356 related radioactivity were markedly lower in all investigated tissues of the DPP-4 deficient rats and the difference of the dose-dependent increase of radioactivity tissue levels between both rat strains indicates that tissue distribution at low doses of BI 1356 is dominated by binding of BI 1356 to DPP-4 in tissues. As the binding to DPP-4 is strong but reversible, the tissue binding results in a long terminal half-life in several tissues including plasma. The binding capacity to DPP-4 is, however, limited. In the rat, saturation of DPP-4 binding is suggested at an intravenous dose above 0.01-0.1 mg/kg [(14)C]BI 1356. As the DPP-4 binding capacity is saturated already at low doses, accumulation of BI 1356 in tissues is unlikely, despite the long persistence of low amounts in the body. Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:229 / 240
页数:12
相关论文
共 17 条
  • [1] [Anonymous], 2004, DRUG DISCOV TODAY
  • [2] Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
    Bergman, Arthur J.
    Cote, Josee
    Yi, Bingming
    Marbury, Thomas
    Swan, Suzanne K.
    Smith, William
    Gottesdiener, Keith
    Wagner, John
    Herman, Gary A.
    [J]. DIABETES CARE, 2007, 30 (07) : 1862 - 1864
  • [3] Is the Fischer 344/CRJ rat a protein-knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer?
    Cheng, HC
    Abdel-Ghany, M
    Zhang, SY
    Pauli, BU
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 1999, 17 (07) : 609 - 615
  • [4] 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes
    Eckhardt, Matthias
    Langkop, Elke
    Mark, Michael
    Tadayyon, Mob
    Thomas, Leo
    Nar, Herbert
    Pfrengle, Waldemar
    Guth, Brian
    Lotz, Ralf
    Sieger, Peter
    Fuchs, Holger
    Himmelsbach, Frank
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (26) : 6450 - 6453
  • [5] ERICKSON RH, 1992, J BIOL CHEM, V267, P21623
  • [6] Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans
    Fuchs, Holger
    Tillement, Jean-Paul
    Urien, Saik
    Greischel, Andreas
    Roth, Willy
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2009, 61 (01) : 55 - 62
  • [7] DIPEPTIDYL PEPTIDASE (DPP)-IV IN RAT ORGANS - COMPARISON OF IMMUNOHISTOCHEMISTRY AND ACTIVITY HISTOCHEMISTRY
    HARTEL, S
    GOSSRAU, R
    HANSKI, C
    REUTTER, W
    [J]. HISTOCHEMISTRY, 1988, 89 (02) : 151 - 161
  • [8] Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
    Heise, T.
    Graefe-Mody, E. U.
    Huettner, S.
    Ring, A.
    Trommeshauser, D.
    Dugi, K. A.
    [J]. DIABETES OBESITY & METABOLISM, 2009, 11 (08) : 786 - 794
  • [9] Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers
    Huettner, S.
    Graefe-Mody, E. U.
    Withopf, B.
    Ring, A.
    Dugi, K. A.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (10) : 1171 - 1178
  • [10] Cell-surface peptidases
    Mentlein, R
    [J]. INTERNATIONAL REVIEW OF CYTOLOGY - A SURVEY OF CELL BIOLOGY, VOL 235, 2004, 235 : 165 - +